• #
    medicine name: Diclotan
  • #
    Generic name: Diclofenac Na
  • #
    Medication Shape: Oral tablets
  • #
    Packing: Diclotan 25: Box of 5 blisters of 20 E.C. tablets. Diclotan 50: Box of 10 blisters of 10 E.C. tablets.
  • #
    Pharmaceutical group: Pain killer


Relief of all grades of pain and inflammation in a wide range of conditions, including:
arthritic conditions: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout,
acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendinitis, tenosynovitis, bursitis,
other painful conditions resulting from trauma, including fracture, low back pain, sprains, strains, dislocations, orthopedic, dental and other minor surgery.

Method of Use:

 Hypersensitivity to diclofenac sodium or to any of the excipients.
 • Active, or gastric or intestinal ulcer, bleeding or perforation.
• History of gastrointestinal bleeding or perforation, relating to previous NSAIDs therapy. • Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
 • Last trimester of pregnancy •Severe hepatic failure
Severe renal failure 
• Established congestive heart failure (NYHA-II-IV), ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
• Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in patients in whom attacks of asthma, angiodema, urticaria or acute rhinitis are precipitated by ibuprofen, acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.

prohibited usage:

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.
 •Adults: 75 mg to 150 mg daily in two or three divided doses. The recommended maximum daily dose of diclofenac sodium is 150mg.
•Children: This medicine is not suitable for children. 
•Elderly: The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy. 
•Renal/Hepatic impairment: Diclofenac is contraindicated in patients with severe renal/hepatic impairment. No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering diclofenac to patients with mild to moderate renal impairment.